Table Info

Table 1.

Summary of laboratory markers (established or candidates) cited in the article, as marker of MetS

Marker	Class	Variation	Type	Eligible	References
Waist circumference	Physical	Increase	Establish	Yes	Fahed et al. [3], 2022
TG	Lipidic profile	Increase	Establish	Yes	Fahed et al. [3], 2022
HDL-C	Lipidic profile	Decrease	Establish	Yes	Fahed et al. [3], 2022
Fasting glucose	Lipidic profile	Increase	Establish	Yes	Fahed et al. [3], 2022
Blood pressure	Lipidic profile	Increase	Establish	Yes	Fahed et al. [3], 2022
TG/HDL-C	Lipidic profile	Increase	Candidate	Yes	Zhang et al. [17], 2022
SdLDL-C	Lipidic profile	Increase	Candidate	No	Hirano et al. [24], 2022
ApoB/ApoA1	Lipidic profile	Increase	Candidate	No	Reynoso-Villalpando et al. [25], 2019
OMEN	Inflammatory function	Decrease	Candidate	No	Makiel et al. [27], 2023
Resistin	Inflammatory function	Increase	Candidate	No	Kim et al. [34], 2022
Visfatin	Inflammatory function	Increase	Candidate	No	Berezin et al. [29], 2020
Activin-A	Inflammatory function	Increase	Candidate	Yes	Peng et al. [42], 2018
Leptin/Adiponectin	Inflammatory function	Increase	Candidate	Yes	Adejumo et al. [32], 2019
TNF-α	Inflammatory function	Increase	Candidate	No	Berezin et al. [29], 2020
IL-6	Inflammatory function	Increase	Candidate	No	Berezin et al. [29], 2020
PAI-1	Inflammatory function	Increase	Candidate	Yes	Kim et al. [34], 2022
AngII	Inflammatory function	Increase	Candidate	No	Ragino et al. [35], 2020
NLRP3	Inflammatory function	Increase	Candidate	No	Lu et al. [39], 2023
TBARS, MDA, 4-HNE, and F2 isoproteins	Oxidative stress	Increase	Candidate	Yes	Masenga et al. [13], 2023
Protein carbonyls, advanced glycation, ox-LDL, and advanced oxidation proteins	Oxidative stress	Increase	Candidate	No	Masenga et al. [13], 2023
8-Oxo-Dg, 5-chlorouracil, and 5-chlorocytosine	Oxidative stress	Increase	Candidate	No	Masenga et al. [13], 2023
Xanthine oxidase, GGT, MPO, NOX, and NOS	Oxidative stress	Increase	Candidate	No	Masenga et al. [13], 2023
Serum ferritin	Oxidative stress	Increase	Candidate	Yes	Masenga et al. [13], 2023

AngII: angiotensin II; GGT: gamma-glutamyl transferase; HDL-C: high density lipoprotein-cholesterol; IL: interleukin; MDA: malonyldialdehyde; MPO: myeloperoxidase; NLRP3: NOD-like receptor family, pyrine domain containing 3; NOS: nitric oxide synthase; NOX: NADPH oxidase; OMEN: omentin; ox-LDL: oxidized-low-density lipoprotein; PAI-1: plasminogen activator inhibitor-1; SdLDL-C: small dense low-density lipoprotein cholesterol; TBARS: thiobarbituric acid reactive substances; TG: triglycerides; TNF-α: tumor necrosis factor α; 8-oxo-Dg: 8-oxo-2-deoxyguanosine; 4-HNE: 4-hydroxy-2-nonenal; ApoA1: apolipoprotein A1; ApoB: apolipoprotein B

Declarations

Author contributions

FM: Conceptualization, Investigation, Writing—original draft. AV: Conceptualization, Writing—review & editing, Validation, Supervision. JM: Writing—review & editing, Validation. LP: Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition. 1997;13:64. [DOI] [PubMed]

Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev. 2020;16:12–8. [DOI] [PubMed]

Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23:786. [DOI] [PubMed] [PMC]

Pirih FQ, Monajemzadeh S, Singh N, Sinacola RS, Shin JM, Chen T, et al. Association between metabolic syndrome and periodontitis: The role of lipids, inflammatory cytokines, altered host response, and the microbiome. Periodontol 2000. 2021;87:50–75. [DOI] [PubMed] [PMC]

McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36:14–20. [DOI] [PubMed]

Prasun P. Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta - Mol Basis Dis. 2020;1866:165838. [DOI]

Alkhulaifi F, Darkoh C. Meal Timing, Meal Frequency and Metabolic Syndrome. Nutrients. 2022;14:1719. [DOI] [PubMed] [PMC]

Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic Syndrome Pathophysiology and Predisposing Factors. Int J Sports Med. 2021;42:199–214. [DOI] [PubMed]

Rojas-Humpire R, Soriano-Moreno DR, Galindo-Yllu B, Zafra-Tanaka JH. Association between Copeptin and Metabolic Syndrome: A Systematic Review. J Nutr Metab. 2022;2022:5237903. [DOI] [PubMed] [PMC]

10.

Noncommunicable diseases [Internet]. WHO; c2024 [cited 2023 Jun 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

11.

Ambroselli D, Masciulli F, Romano E, Catanzaro G, Besharat ZM, Massari MC, et al. New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. Nutrients. 2023;15:640. [DOI] [PubMed] [PMC]

12.

Lu YW, Chang CC, Chou RH, Tsai YL, Liu LK, Chen LK, et al. Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study. Cardiovasc Diabetol. 2021;20:206. [DOI] [PubMed] [PMC]

13.

Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int J Mol Sci. 2023;24:7898. [DOI] [PubMed] [PMC]

14.

nigms.nih.gov [Internet]. [Cited 2024 Jan 4]. Available from: https://www.nigms.nih.gov

15.

Orozco-Solis R, Sassone-Corsi P. Epigenetic control and the circadian clock: Linking metabolism to neuronal responses. Neuroscience. 2014;264:76–87. [DOI] [PubMed] [PMC]

16.

Son DH, Ha HS, Park HM, Kim HY, Lee YJ. Chapter Two - New markers in metabolic syndrome. In: Makowski GS, editor. Advances in Clinical Chemistry. Elsevier. 2022. pp. 37–71. [DOI]

17.

Zhang JS, Yeh WC, Tsai YW, Chen JY. The Relationship between Atherogenic Index of Plasma and Obesity among Adults in Taiwan. Int J Environ Res Public Health. 2022;19:14864. [DOI] [PubMed] [PMC]

18.

Srivastava S, Aditi P, Yadav D. Gut microbiome and the metabolic syndrome. In: Keservani RK, Yadav D, Kesharwani RK, Singh S, Sandeep K, editors. The Metabolic Syndrome. New York: Apple Academic Press; 2023. pp. 121–37.

19.

Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, et al. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2021;13:320. [DOI] [PubMed] [PMC]

20.

Lechner K, Lechner B, Crispin A, Schwarz PEH, von Bibra H. Waist-to-height ratio and metabolic phenotype compared to the Matsuda index for the prediction of insulin resistance. Sci Rep. 2021;11:8224. [DOI] [PubMed] [PMC]

21.

Singh B, Arora S, Goswami B, Mallika V. Metabolic syndrome: A review of emerging markers and management. Diabetes Metab Syndr Clin Res Rev. 2009;3:240–54. [DOI]

22.

Mancusi C, Izzo R, di Gioia G, Losi MA, Barbato E, Morisco C. Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes. High Blood Press Cardiovasc Prev. 2020;27:515–26. [DOI] [PubMed] [PMC]

23.

Cardiovascular diseases (CVDs) [Internet]. WHO; c2024 [cited 2024 Jan 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

24.

Hirano T, Kodera R, Hirashima T, Suzuki N, Aoki E, Hosoya M, et al. Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. J Atheroscler Thromb. 2022;29:762–74. [DOI] [PubMed] [PMC]

25.

Reynoso-Villalpando GL, Sevillano-Collantes C, Valle Y, Moreno-Ruiz I, Padilla-Gutiérrez JR, Del Cañizo-Gómez FJ. ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. Endocrinol Diabetes Nutr (Engl Ed). 2019;66:502–11. English, Spanish. [DOI] [PubMed]

26.

Khanna D, Welch BS, Rehman A. Pathophysiology of Obesity. Treasure Island (FL): StatPearls Publishing; 2024. [PubMed]

27.

Makiel K, Suder A, Targosz A, Maciejczyk M, Kozioł-Kozakowska A, Haim A. Impact of Two Types of Exercise Interventions on Leptin and Omentin Concentrations and Indicators of Lipid and Carbohydrate Metabolism in Males with Metabolic Syndrome. J Clin Med. 2023;12:2822. [DOI] [PubMed] [PMC]

28.

Çelik M, Nar R, Nar G, Sökmen E, Günver G. Serum omentin-1 levels in hypertensive patients. J Hum Hypertens. 2021;35:290–5. [DOI] [PubMed]

29.

Berezin AE, Berezin AA, Lichtenauer M. Emerging Role of Adipocyte Dysfunction in Inducing Heart Failure Among Obese Patients With Prediabetes and Known Diabetes Mellitus. Front Cardiovasc Med. 2020;7:583175. [DOI] [PubMed] [PMC]

30.

Falahi E, Khalkhali Rad AH, Roosta S. What is the best biomarker for metabolic syndrome diagnosis? Diabetes Metab Syndr. 2015;9:366–72. [DOI] [PubMed]

31.

Zaiou M. Circular RNAs as Potential Biomarkers and Therapeutic Targets for Metabolic Diseases. Adv Exp Med Biol. 2019;1134:177–91. [DOI] [PubMed]

32.

Adejumo EN, Adejumo OA, Azenabor A, Ekun AO, Enitan SS, Adebola OK, et al. Leptin: Adiponectin ratio discriminated the risk of metabolic syndrome better than adiponectin and leptin in Southwest Nigeria. Diabetes Metab Syndr. 2019;13:1845–9. [DOI] [PubMed]

33.

Ramirez JL, Khetani SA, Zahner GJ, Spaulding KA, Schaller MS, Gasper WJ, et al. Serum resistin is associated with impaired endothelial function and a higher rate of adverse cardiac events in patients with peripheral artery disease. J Vasc Surg. 2019;69:497–506. [DOI] [PubMed] [PMC]

34.

Kim JE, Kim JS, Jo MJ, Cho E, Ahn SY, Kwon YJ, et al. The Roles and Associated Mechanisms of Adipokines in Development of Metabolic Syndrome. Molecules. 2022;27:334. [DOI] [PubMed] [PMC]

35.

Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review. Biomolecules. 2020;10:374. [DOI] [PubMed] [PMC]

36.

Ravaut G, Légiot A, Bergeron KF, Mounier C. Monounsaturated Fatty Acids in Obesity-Related Inflammation. Int J Mol Sci. 2020;22:330. [DOI] [PubMed] [PMC]

37.

O’Neill BJ. Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome. Curr Opin Endocrinol Diabetes Obes. 2020;27:301–7. [DOI] [PubMed]

38.

Zhu XX, Zhang WW, Wu CH, Wang SS, Smith FG, Jin SW, et al. The Novel Role of Metabolism-Associated Molecular Patterns in Sepsis. Front Cell Infect Microbiol. 2022;12:915099. [DOI] [PubMed] [PMC]

39.

Lu S, Li Y, Qian Z, Zhao T, Feng Z, Weng X, et al. Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Front Immunol. 2023;14:1052756. [DOI] [PubMed] [PMC]

40.

Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020;21:1835. [DOI] [PubMed] [PMC]

41.

Haverinen E, Fernandez MF, Mustieles V, Tolonen H. Metabolic Syndrome and Endocrine Disrupting Chemicals: An Overview of Exposure and Health Effects. Int J Environ Res Public Health. 2021;18:13047. [DOI] [PubMed] [PMC]

42.

Peng LN, Chou MY, Liang CK, Lee WJ, Kojima T, Lin MH, et al. Association between serum activin A and metabolic syndrome in older adults: Potential of activin A as a biomarker of cardiometabolic disease. Exp Gerontol. 2018;111:197–202. [DOI] [PubMed]

43.

Zeller J, Krüger C, Lamounier-Zepter V, Sag S, Strack C, Mohr M, et al. The adipo-fibrokine activin A is associated with metabolic abnormalities and left ventricular diastolic dysfunction in obese patients. ESC Heart Fail. 2019;6:362–70. [DOI] [PubMed] [PMC]

44.

Litwin M, Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol. 2021;36:825–37. [DOI] [PubMed] [PMC]